Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Mantle-Cell 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia 3Waldenstrom Macroglobulinemia 2Melanoma 2Lymphoma, Non-Hodgkin 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Myeloid, Acute 2Burkitt Lymphoma 2Unspecified Adult Solid Tumor, Protocol Specific 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Intraocular Lymphoma 1Hodgkin Disease 1Gastrointestinal Stromal Tumors 1Extensive Stage Small Cell Lung Cancer 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 77Paclitaxel 48Trastuzumab 40Tamoxifen 39Doxorubicin 37Docetaxel 35Radiotherapy 32Fluorouracil 26Chemotherapy, Adjuvant 26Taxes 23Epirubicin 22Carboplatin 22Filgrastim 21Specimen Handling 19Methotrexate 19Magnetic Resonance Spectroscopy 19Neoadjuvant Therapy 18aldesleukin 16Peripheral Blood Stem Cell Transplantation 16Bevacizumab 13Lapatinib 12CMF regimen 12Anastrozole 12exemestane 11Goserelin 11Capecitabine 11Biopsy 11veliparib 10sargramostim 10fludarabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Breast Neoplasms × oblimersen × Clear all
NCT00063934 2019-03-05

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Terminated
31 enrolled 8 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡